-+ 0.00%
-+ 0.00%
-+ 0.00%

*Keros Therapeutics Expects Cash and Cash Equivalents to Fund Oper Expenses and Cap Expenditures Into 1H 2028 >KROS

Dow Jones·08/03/2026 20:02:00

Please log in to view news